PCRX Q3'26 Earnings: EPS estimate is 0.73 USD

What happened

Pacira BioSciences is set to announce its Q3'26 results on October 29 at 8:00 AM ET. The revenue estimate is 182.87 million USD and the EPS estimate is 0.73 USD.

Confirmed

Global impact / market context

These estimates give investors a benchmark for judging the results. If actual revenue or profit per sale, which means earnings per share, falls short, the stock could face pressure; a beat may support the shares.

Analyst inference

Prior quarters show Pacira has both beaten and missed estimates, so surprises are possible. The most recent reported quarter matched the 0.73 USD EPS estimate, suggesting expectations are already reflected in the current numbers.

Analyst inference

What to watch

1. The Q3'26 results are scheduled for October 29 at 8:00 AM ET, with revenue estimated at 182.87 million USD and EPS estimated at 0.73 USD. Confirmed
2. Compare actual revenue to the 182.87 million USD estimate and EPS to 0.73 USD; a miss could pressure the stock, while a beat could support it. Analyst inference
3. Watch whether Pacira repeats its recent pattern of revenue surprises, since past quarters ranged from a 0.88% miss to a 3.25% beat. Analyst inference

Evidence

• Original source link unavailable